Jardiance vs Farxiga: SGLT2 Inhibitor Head-to-Head

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Jardiance vs Farxiga: SGLT2 Inhibitor Head-to-Head

Quick Answer: Jardiance (empagliflozin) and Farxiga (dapagliflozin) are the two most-prescribed SGLT2 inhibitors in the world and they are clinically very similar — both lower HbA1c by ~0.6–0.8%, produce ~2–3 kg weight loss, and have positive cardiovascular and renal outcome data. The clinically meaningful differences are subtle: Jardiance has the stronger mortality signal (EMPA-REG OUTCOME), Farxiga the broadest CKD evidence (DAPA-CKD enrolled non-diabetics), and Farxiga the lower starting price. For most patients, choosing between them is more about access and cost than meaningful clinical difference. This guide gives the full comparison.

Same Mechanism, Different Molecules

Both drugs are selective inhibitors of sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule. SGLT2 normally reabsorbs ~90% of filtered glucose. Inhibition causes 50–100 g of glucose to be excreted daily in the urine — independent of insulin — producing osmotic diuresis (small natriuresis and water loss), modest caloric loss (200–400 kcal/day), and a measurable reduction in arterial pressure.

Empagliflozin (Jardiance)

Approved 2014. Highest SGLT2 selectivity in the class (>2600-fold over SGLT1). Half-life 12.4 hours; once-daily dosing. Manufactured by Boehringer Ingelheim. WHO-GMP generic available as Jardiance (Empagliflozin); combination products include Glyxambi (empagliflozin + linagliptin).

Dapagliflozin (Farxiga / Forxiga)

Approved 2014 (EU) / 2014 (US). High SGLT2 selectivity (~1200-fold). Half-life ~12.9 hours; once-daily dosing. Manufactured by AstraZeneca. WHO-GMP generic available as Forxiga (Dapagliflozin).

Head-to-Head Comparison

The Outcome Trials — Where the Differences Live

EMPA-REG OUTCOME (Jardiance, 2015)

The first cardiovascular outcome trial of an SGLT2 inhibitor changed diabetes management overnight. 7,020 Type 2 diabetics with established CVD randomised to empagliflozin or placebo. Results:

• −14% in three-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke)
• −38% in cardiovascular death — driven almost entirely by reduced HF mortality and sudden death
• −35% in hospitalisation for heart failure
• −39% in worsening nephropathy

DECLARE-TIMI 58 (Farxiga, 2019)

17,160 Type 2 diabetics with established CVD OR multiple risk factors. Lower-risk population than EMPA-REG. Results:

• Co-primary MACE: not significantly different (HR 0.93, p=0.17)
• Co-primary CV death + HHF: −17% (driven by HHF)
• −27% in hospitalisation for heart failure
• −24% renal composite endpoint

DECLARE’s “softer” MACE result reflects the lower baseline CV risk in its enrolled population, not weaker drug effect.

DAPA-HF and DAPA-CKD: Farxiga’s Expansion Beyond Diabetes

Research spotlight: DAPA-HF (2019, NEJM) randomised 4,744 patients with HFrEF (EF ≤40%), with or without diabetes, to dapagliflozin or placebo. Composite of worsening HF or CV death reduced 26%. DAPA-CKD (2020, NEJM) randomised 4,304 CKD patients, with or without diabetes, to dapagliflozin or placebo. Composite of ≥50% eGFR decline, ESRD, or death reduced 39%. Both trials made dapagliflozin the first SGLT2 inhibitor approved in non-diabetic HF and non-diabetic CKD. Empagliflozin (EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY) followed with comparable data, but Farxiga’s earlier non-diabetic indications are why some clinicians still default to it for that use case.

When to Choose Which

The honest answer: For most patients, either drug is fine. The class effect is dominant; molecule-specific differences are subtle. Use whichever is more affordable, more available, or already in your formulary. Where differences matter:

Prefer Jardiance (Empagliflozin) If:

• You have established cardiovascular disease + Type 2 diabetes and CV mortality reduction is the priority — EMPA-REG showed −38% CV death; DECLARE was neutral on CV death
• You want the longest cardiovascular outcome dataset
• You have HFpEF — EMPEROR-Preserved was the first trial to show clear benefit in this phenotype

Prefer Farxiga (Dapagliflozin) If:

• You have HFrEF without diabetes — DAPA-HF was the first SGLT2 trial in non-diabetic HF and remains the strongest evidence base for this group
• You have CKD without diabetes — DAPA-CKD has the strongest non-diabetic CKD evidence
• Cost or access is meaningfully better for Farxiga in your market
• You have lower-risk Type 2 diabetes where MACE prevention isn’t the priority

Avoid Both If:

• You have Type 1 diabetes — significantly increased DKA risk; only approved with caution as adjunct in select populations
• You have severe CKD with eGFR < 20 (initiation thresholds vary; once eGFR drops below 20 mL/min/1.73 m² on therapy, continuation is acceptable; new initiation usually paused)
• You have a history of recurrent UTIs, genital fungal infections, or severe Fournier’s gangrene risk
• You are pregnant or planning pregnancy — neither is recommended

Class-Wide Side Effects (Both Drugs)

Common

• Genital mycotic infections — 5–10% of women, 1–3% of men; higher in uncircumcised men. Most respond to topical antifungals; rarely necessitate stopping the drug.
• UTI — slightly increased rate; manage standardly
• Volume depletion symptoms — light-headedness on standing, dizziness, mild dehydration; matters most in elderly or on diuretics
• Polyuria/nocturia — typical, usually settles after 4–6 weeks

Uncommon but Important

• Euglycaemic DKA — rare in T2DM; higher risk during fasting, alcohol use, low-carb diets, surgery. Pause drug 3 days before elective surgery; restart only when eating normally.
• Fournier’s gangrene — extremely rare necrotising fasciitis of the perineum; FDA warning issued 2018. Total reported cases globally remain low.
• Lower limb amputation — signal seen in CANVAS for canagliflozin; not seen in empagliflozin or dapagliflozin trials. Class label retains a caution.

Generic Pricing Has Closed the Gap

Both drugs have generic versions available in many global markets. WHO-GMP empagliflozin and dapagliflozin from manufacturers like Sun Pharma, Cipla, and Dr Reddy’s are typically $15–$40 per month — a fraction of the $600+ branded US price. In markets where both generics are available, the price difference between Jardiance and Farxiga generics is usually under 20%, making clinical fit the more important selection factor.

How They Fit With Other Diabetes Drugs

• Foundation: Metformin (Diabetes Starter Pack) — see Jardiance vs Metformin
• Layered classes:
  • SGLT2 — Jardiance / Farxiga (this article)
  • GLP-1 — semaglutide; see Ozempic vs Metformin
  • DPP-4 — sitagliptin; see Januvia vs Metformin
  • Sulfonylurea — glimepiride; see Glimepiride vs Metformin
  • TZD — pioglitazone; see Pioglitazone vs Metformin
• For patients with cardiovascular disease or heart failure: SGLT2 + GLP-1 + metformin is becoming the standard “triple-mechanism” backbone

Frequently Asked Questions

Are Jardiance and Farxiga interchangeable?

Clinically very close — same mechanism, similar HbA1c effect, similar weight loss, similar BP reduction. The subtle differences (Jardiance’s CV mortality edge, Farxiga’s non-diabetic HF/CKD priority) matter for specific phenotypes. For routine Type 2 diabetes management, either is acceptable.

Can I switch between them?

Yes — start the new drug the day after stopping the old one. No washout needed. Monitor as you would normally.

What about the third SGLT2 inhibitor, Invokana (canagliflozin)?

Canagliflozin has positive CV and renal outcome data (CANVAS, CREDENCE) but also showed a small increase in lower-limb amputations not seen with empagliflozin or dapagliflozin. Most clinicians now prefer Jardiance or Farxiga as first-choice SGLT2 inhibitors. Invokana remains in use, particularly for renal indications.

Do I need to drink more water on SGLT2 inhibitors?

Yes — they cause modest diuresis. Maintain regular fluid intake. The volume-depletion signal is highest in elderly patients on loop diuretics; your loop diuretic dose may need to be reduced after starting an SGLT2.

Will an SGLT2 inhibitor protect my kidneys?

Yes — both have strong evidence for slowing CKD progression in Type 2 diabetes (EMPA-KIDNEY, DAPA-CKD), and Farxiga additionally has strong evidence in non-diabetic CKD. The mechanism appears to be reduction of glomerular hyperfiltration via tubuloglomerular feedback.

Can I take SGLT2 inhibitors with metformin?

Yes — extensively co-prescribed. Both lower HbA1c independently and the combination is one of the best-evidenced T2DM regimens for patients with cardiovascular or renal risk. Glyxambi (Glyxambi) is a related fixed-dose option (empagliflozin + linagliptin).

Medical Disclaimer: SGLT2 inhibitor selection should be based on individual cardiovascular and renal profile, comorbidities, and side-effect tolerance. Baseline eGFR, volume status, and infection-risk assessment are advised before initiation. Always work with a qualified healthcare provider for therapy decisions.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.